Avtor/Urednik		Džajkovska, Biljana
Naslov		Pharmacoeconomic analysis of different drug treatments for osteoporosis
Prevedeni naslov		Farmakoekonomska analiza različnih zdravljenj osteoporoze
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		2003
Obseg		str. 143
Jezik		eng
Abstrakt		Background: Osteoporosis is a chronic disease with serious socioeconomic impact worldwide because of its huge prevalence, and enormous costs associated with treatment of this condition and its consequences, i.e. fractures. Objective: To perform pharmacoeconomic analysis with the aim to evaluate and compare all available treatments for osteoporosis, in order to optimize the efficiency of osteoporosis treatments and therewith management of this serious healthcare problem. Design and perspective: A retrospective, modeled pharmacoeconomic analysis of different treatment regimens for osteoporosis was performed from the widest, societal perspective. Analyses included postmenopausal women divided in four age groups: 50-64 years, 65-74 years, 75-84 years, and over 85 years, respectively. The following seven treatment options were analyzed: no drug therapy, alendronate, etidronate, risedronate, calcitonin, hormone replacement therapy, and raloxifene. Methods: Data on clinical efficacy of osteoporotic regimens were pooled from published meta-analyses and randomized controlled trials. Economic analysis was performed on the basis of a Markov model developed with decision analytical software using data on probabilities and costs derived from Slovenian sources. Results: Results of our cost-effectiveness and cost-utility analysis suggest that hormone replacement therapy is the most cost-effective treatment option for women in the age group SO-64; alendronate and hormone replacement therapy are best options for treating women aged 65-74; with the increasing age, even more expensive treatments such as calcitonin and risedronate are cost-effective and justified besides alendronate and hormone replacement therapy. However, raloxifene and etidronate failed to be cost-effective in our analysis in all scenarios. (Abstract truncated at 2000 characters).
Deskriptorji		OSTEOPOROSIS DRUG COSTS DIPHOSPHONATES CALCITONIN ESTROGEN REPLACEMENT THERAPY MIDDLE AGE AGED COST-BENEFIT ANALYSIS FRACTURES, SPONTANEOUS INSURANCE, HEALTH SPINAL FRACTURES RECEPTORS, ESTROGEN HOSPITALIZATION AMBULATORY CARE TREATMENT OUTCOME RETROSPECTIVE STUDIES